Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis (IRIS)

First posted November 30, 2021, Updated May 20, 2022; Recruiting

This Phase 3, multicenter, multinational, randomized, double-blind, placebo-controlled study will evaluate the efficacy and safety of anifrolumab versus placebo as added to SOC (consisting of MMF and glucocorticoids) in adults with active proliferative Class III or Class IV LN (both with or without concomitant Class V).

To Learn More Contact

Contact: AstraZeneca Clinical Study Information at 1-877-240-9479 or information.center@astrazeneca.com

ClinicalTrials.gov identifier (NCT number): NCT05138133